NCT04221152View on ClinicalTrials.gov

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

PHASE3UnknownINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

February 1, 2022

Study Completion Date

May 31, 2022

Conditions
Insulin Resistance - Type AInsulin Resistance - Type BLipoatrophic Diabetes MellitusInsulin Resistance Syndrome
Interventions
DRUG

Empagliflozin Tablets

The administration is oral administration with water before or after breakfast.

Trial Locations (5)

650-0017

Kobe University Hospital, Kobe

980-8574

Tohoku University Hospita, Sendai

329-0498

Jichi Medical University Hospital, Shimotsuke

101-8309

NIhon University Hospital, Chiyoda-ku

700-8558

Okayama University Hospital, Okayama

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Kobe University

INDUSTRY

NCT04221152 - A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 ) | Biotech Hunter | Biotech Hunter